Virtus KAR Health Sciences Fund Inst (HLHIX)
30.09
-0.24
(-0.79%)
USD |
Nov 20 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.05% | 103.53M | 0.86% | 8.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -25.99M | 2.38% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation by investing at least 65% of its assets in healthcare sector equity securities. Under normal market conditions, the fund will invest at least 65% of its assets will be invested in companies located in at least three different countries, including possibly the United States. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Virtus |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
47
-200.62M
Peer Group Low
1.257B
Peer Group High
1 Year
% Rank:
39
-25.99M
-3.084B
Peer Group Low
87.16M
Peer Group High
3 Months
% Rank:
47
-709.11M
Peer Group Low
543.86M
Peer Group High
3 Years
% Rank:
41
-8.144B
Peer Group Low
209.03M
Peer Group High
6 Months
% Rank:
40
-1.459B
Peer Group Low
138.07M
Peer Group High
5 Years
% Rank:
43
-7.432B
Peer Group Low
3.629B
Peer Group High
YTD
% Rank:
38
-2.408B
Peer Group Low
81.76M
Peer Group High
10 Years
% Rank:
45
-13.02B
Peer Group Low
5.589B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of November 21, 2025.
Asset Allocation
As of June 30, 2025.
| Type | % Net |
|---|---|
| Cash | 0.00% |
| Stock | 98.22% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 1.78% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 13.74% | 1043.29 | -0.60% |
| AbbVie, Inc. | 6.25% | 229.45 | -1.49% |
| McKesson Corp. | 6.11% | 849.46 | -0.35% |
| Intuitive Surgical, Inc. | 5.53% | 552.23 | -2.20% |
| IDEXX Laboratories, Inc. | 5.15% | 689.35 | -1.11% |
| Vertex Pharmaceuticals, Inc. | 4.89% | 422.32 | 0.31% |
| DexCom, Inc. | 4.16% | 58.42 | -2.19% |
| HealthEquity, Inc. | 4.07% | 100.73 | -2.72% |
| The Cooper Cos., Inc. | 3.92% | 71.11 | -1.44% |
| Zoetis, Inc. | 3.86% | 115.89 | -1.02% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.73% |
| Administration Fee | 9.07K% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1.00M None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation by investing at least 65% of its assets in healthcare sector equity securities. Under normal market conditions, the fund will invest at least 65% of its assets will be invested in companies located in at least three different countries, including possibly the United States. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Virtus |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (11-19-25) | 0.67% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 24 |
| Stock | |
| Weighted Average PE Ratio | 41.73 |
| Weighted Average Price to Sales Ratio | 7.905 |
| Weighted Average Price to Book Ratio | 12.53 |
| Weighted Median ROE | 37.13% |
| Weighted Median ROA | 10.17% |
| ROI (TTM) | 15.20% |
| Return on Investment (TTM) | 15.20% |
| Earning Yield | 0.0307 |
| LT Debt / Shareholders Equity | 2.420 |
| Number of Equity Holdings | 23 |
As of June 30, 2025
Growth Metrics
| EPS Growth (1Y) | 26.14% |
| EPS Growth (3Y) | 12.86% |
| EPS Growth (5Y) | 16.92% |
| Sales Growth (1Y) | 12.36% |
| Sales Growth (3Y) | 9.40% |
| Sales Growth (5Y) | 12.32% |
| Sales per Share Growth (1Y) | 13.11% |
| Sales per Share Growth (3Y) | 10.25% |
| Operating Cash Flow - Growth Rate (3Y) | 6.38% |
As of June 30, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:HLHIX", "name") |
| Broad Asset Class: =YCI("M:HLHIX", "broad_asset_class") |
| Broad Category: =YCI("M:HLHIX", "broad_category_group") |
| Prospectus Objective: =YCI("M:HLHIX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |